Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Temozolomide met of zonder veliparib bij de behandeling van patiënten met recidiverende of refractaire kleincellige longkanker

11 november 2026 bijgewerkt door: National Cancer Institute (NCI)

Een multicenter, gerandomiseerde, dubbelblinde fase II-studie waarin ABT-888, een PARP-remmer, wordt vergeleken met placebo met temozolomide bij patiënten met recidiverende gevoelige of refractaire kleincellige longkanker

This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment. Temozolomide works by damaging molecules inside the cancer cells, such as deoxyribonucleic acid (DNA), that are needed for cancer survival and growth. Veliparib may stop the growth of tumor cells by blocking proteins that are needed for repairing the damaged DNA and it may also help temozolomide to kill more cancer cells. It is not yet know whether temozolomide is more effective with or without veliparib in treating patients with relapsed or refractory small cell lung cancer.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

PRIMARY OBJECTIVES:

I. To demonstrate an improvement in progression free survival (PFS) at four months in patients with relapsed sensitive or refractory small cell lung cancer (SCLC) receiving ABT-888 (veliparib) and temozolomide compared to placebo and temozolomide.

SECONDARY OBJECTIVES:

I. Determine the objective response rate (ORR) (based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) in both arms of the study: ABT-888 and temozolomide and placebo and temozolomide.

II. Determine the overall survival (OS) of patients in both arms of the study. III. Determine the ORR, PFS and OS of ABT-888 and temozolomide and placebo and temozolomide, in the following patient groups: sensitive disease vs. refractory disease; second-line treatment vs. third-line treatment; brain metastases vs. no brain metastases.

IV. Determine the safety and tolerability of ABT-888 and temozolomide in patients with SCLC.

TERTIARY OBJECTIVES:

I. Evaluate available tumor samples for methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter by the EpiTyper assay, as well as MGMT expression by immunohistochemistry and determine if these correlate with PFS, ORR, and OS.

II. Evaluate available tumor samples for poly (ADP ribose) polymerase (PARP)-1, breast cancer 1 (BRCA-1) and RAD51 recombinase (RAD51) expression by immunohistochemistry and determine if they correlate with PFS, ORR, and OS.

III. Evaluate available tumor samples for messenger ribonucleic acid (mRNA) BRCA-1 expression and determine if it correlates PFS, ORR, and OS.

IV. Evaluate available tumor samples for phosphatase and tensin homolog (PTEN) expression by immunohistochemistry and determine if it correlates PFS, ORR, and OS.

V. Identify and enumerate circulating tumor cells (CTCs) using the Cell Search System in these patients with SCLC at baseline and at the time of repeat imaging.

VI. Correlate the number of CTCs with PFS and OS at each time point. VII. Correlate the change in CTCs with radiographic response. VIII. Correlate the number of CTCs at baseline with patient characteristics (disease burden, location of metastases, progression at existing sites or new sites of disease).

IX. Evaluate gamma H2A histone family, member X (H2AX)-positive CTCs using the CellSearch.

X. Assess the percentage increase in DNA fragments during treatment and correlate with outcome in each of the treatment groups.

XI. Evaluate plasma markers for apoptosis and angiogenesis. XII. Assess changes in plasma markers for apoptosis and angiogenesis, including caspase-cleaved cytokeratin 18 fragment (M30), soluble cytokeratin 18 (M65), pro-gastrin-releasing peptide (pro-GRP), soluble vascular endothelial growth factor (sVEGF), sVEGF receptor 2 (sVEGFR2), and soluble v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (sKIT), and correlate these markers with outcome in the two treatment arms.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive veliparib orally (PO) twice daily (BID) on days 1-7 and temozolomide PO on days 1-5.

ARM II: Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 8-12 weeks.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

97

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigde Staten
    • Florida
      • Tampa, Florida, Verenigde Staten, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Emory University Hospital/Winship Cancer Institute
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Verenigde Staten, 21224
        • Johns Hopkins Bayview Medical Center
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Washington University School of Medicine
    • New Jersey
      • Basking Ridge, New Jersey, Verenigde Staten, 07920
        • Memorial Sloan Kettering Basking Ridge
    • New York
      • Commack, New York, Verenigde Staten, 11725
        • Memorial Sloan Kettering Commack
      • New York, New York, Verenigde Staten, 10065
        • Memorial Sloan Kettering Cancer Center
      • Sleepy Hollow, New York, Verenigde Staten, 10591
        • Memorial Sloan Kettering Sleepy Hollow
      • Uniondale, New York, Verenigde Staten, 11553
        • Memorial Sloan Kettering Nassau
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27599
        • UNC Lineberger Comprehensive Cancer Center
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44106
        • Case Western Reserve University
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • UT MD Anderson Cancer Center
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23298
        • VCU Massey Comprehensive Cancer Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed small cell lung cancer; confirmation will be done at Memorial Sloan-Kettering Cancer Center (MSKCC) or locally for participating sites

  • Patients' disease has relapsed or progressed after one or two prior chemotherapy regimens, one of which must have been an etoposide-platinum doublet; eligible patients will be defined as follows:

    • "Sensitive" disease: patients who had one previous line of chemotherapy and maintained an appropriate response for > 60 days
    • "Refractory" disease: those patients with either (a) no response to first-line chemotherapy or progression =< 60 days after completing treatment, or (b) "sensitive" or "refractory" disease in need of third-line therapy (i.e. completed or failed two previous lines of chemotherapy)

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)

  • Patients with asymptomatic brain metastases that do not require immediate whole brain radiation therapy and are on stable doses of steroids are allowed

  • Patients must have measurable disease, which is defined as at least one lesion that can be accurately measured in at least one dimension on a computed tomography (CT) scan as per RECIST version 1.1; brain metastases can be considered measurable disease if they meet this criterion

  • Absolute neutrophil count >= 1,500/mcL

  • Platelets >= 100,000/mcL

  • Hemoglobin >= 8.5 g/dL; the use of transfusion to achieve this criterion should be at the discretion of the investigators

  • Total bilirubin =< 1.5 mg/dL x institutional upper limit of normal

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional upper limit of normal

  • Creatinine =< 1.5 x institutional upper limit of normal OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels >= 1.5 x upper limit of institutional normal

  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

  • For women of child-bearing potential, negative pregnancy test within 14 days prior to starting temozolomide and ABT-888

  • Ability to understand and the willingness to sign a written informed consent document

  • Able to swallow pills

  • Patients will not be excluded based on the diagnosis of acquired immune deficiency syndrome (AIDS); given the increased risk of infection, these patients should have cluster of differentiation (CD)4 counts above 200 cells/mm^3; patients with AIDS or human immunodeficiency virus (HIV) not receiving agents with the potential for pharmacokinetic interactions with ABT-888 may be eligible

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study
  • Patients who have not recovered from adverse events due to agents administered more than 3 weeks earlier; toxicities should have resolved to baseline or to within one grade level of their baseline (not to exceed grade 2)
  • Patients who have been administered ABT-888, any other PARP-inhibitor, or temozolomide
  • Patients may not be receiving any other investigational agents
  • Patients with leptomeningeal involvement
  • Patients with active seizures or a history of seizures
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or temozolomide
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks also apply to temozolomide
  • Patients with either AIDS or HIV on combination antiretroviral therapy are ineligible
  • Patients with a synchronous active malignancy requiring treatment

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm I (veliparib and temozolomide)

Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
Ander: Laboratory Biomarker Analysis

Correlative studies

Geneesmiddel: Temozolomide

Given PO

Andere namen:
  • Temodar
  • SCH 52365
  • Temodaal
  • Temcad
  • Methazolasteen
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M en B 39831
  • Glioteem
  • Temizol
Geneesmiddel: Veliparib

Given PO

Andere namen:
  • ABT-888
  • PARP-1-remmer ABT-888
  • ABT 888
  • ABT888
Actieve vergelijker: Arm II (placebo and temozolomide)

Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
Ander: Laboratory Biomarker Analysis

Correlative studies

Ander: Placebo Administration

Given PO

Geneesmiddel: Temozolomide

Given PO

Andere namen:
  • Temodar
  • SCH 52365
  • Temodaal
  • Temcad
  • Methazolasteen
  • RP-46161
  • Temomedac
  • TMZ
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M en B 39831
  • Glioteem
  • Temizol

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease
Tijdsspanne: From randomization to time of progression or death, whichever occurs first, assessed at 4 months

Compared across the two arms using a Fisher exact test.
From randomization to time of progression or death, whichever occurs first, assessed at 4 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall Response (ORR) by RECIST 1.1 Criteria
Tijdsspanne: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months

Corresponding exact two-sided 95% confidence intervals will be calculated and reported in both arms of the study. Comparisons between treatment arms will be performed using Fisher-exact test.
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months
Overall Survival
Tijdsspanne: From randomization to time of death

Estimated in each treatment group using Kaplan-Meier method. Group comparisons will be performed using log-rank test.
From randomization to time of death
Number of Participants With Adverse Events
Tijdsspanne: From the start of treatment until 30 days from coming off treatment

Tabulated According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Summary level.
From the start of treatment until 30 days from coming off treatment

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
BRCA1 Expression, Assessed by Immunohistochemistry
Tijdsspanne: Up to 5 years

Fisher's exact test will be used to correlate response and log-rank test to correlate with progression free survival and overall survival.
Up to 5 years
Changes in Plasma Markers
Tijdsspanne: Baseline to up to 5 years

Correlated with outcome in the two treatment arms.
Baseline to up to 5 years
GammaH2AX Levels
Tijdsspanne: Up to 5 years

Wilcoxon test will be used to compare the percentage increase of gammaH2AX positive cells between the two treatment groups.
Up to 5 years
MGMT Expression, Assessed by Immunohistochemistry
Tijdsspanne: Up to 5 years

Results will be expressed as binary variables. Associations with objective response, with progression free survival and with overall survival will be tested using Fisher's exact test and log-rank test, respectively.
Up to 5 years
Number of Circulating Tumor Cells
Tijdsspanne: Up to 5 years

The number of CTCs will be correlated with PFS and OS using Cox proportional hazards model. The change in CTCs will be correlated with radiographic response. The number of CTCs at baseline will be correlated with patient characteristics (disease burden, location of metastases, and progression at existing sites or new sites of disease). The number of CTC will be explored as a continuous variable and the presence of a threshold predictive of the outcome will be investigated.
Up to 5 years
PARP-1 Expression
Tijdsspanne: Up to 5 years

Fisher's exact test will be used to correlate response and log-rank test to correlate with progression free survival and overall survival.
Up to 5 years
Presence of MGMT Promoter Methylation, Assessed by the EpiTyper Assay
Tijdsspanne: Up to 5 years

Results will be expressed as binary variables. Associations with objective response, with progression free survival and with overall survival will be tested using Fisher's exact test and log-rank test, respectively.
Up to 5 years
PTEN Expression, Assessed by Immunohistochemistry
Tijdsspanne: Up to 5 years

Fisher's exact test will be used to correlate response and log-rank test to correlate with progression free survival and overall survival.
Up to 5 years
RAD51 Expression, Assessed by Immunohistochemistry
Tijdsspanne: Up to 5 years

Fisher's exact test will be used to correlate response and log-rank test to correlate with progression free survival and overall survival.
Up to 5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

National Cancer Institute (NCI)

Onderzoekers

  • Hoofdonderzoeker: Charles M Rudin, Memorial Sloan Kettering Cancer Center

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 juli 2012

Primaire voltooiing (Werkelijk)

9 januari 2017

Studie voltooiing (Geschat)

25 maart 2027

Studieregistratiedata

Eerst ingediend

9 juli 2012

Eerst ingediend dat voldeed aan de QC-criteria

9 juli 2012

Eerst geplaatst (Geschat)

11 juli 2012

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NCI-2012-01130
  • U01CA070095 (Subsidie/contract van de Amerikaanse NIH)
  • UM1CA186691 (Subsidie/contract van de Amerikaanse NIH)
  • P30CA008748 (Subsidie/contract van de Amerikaanse NIH)
  • N01CM00039 (Subsidie/contract van de Amerikaanse NIH)
  • 9026 (Andere identificatie: CTEP)
  • NCI-2012-01130 (Register-ID: CTRP (Clinical Trial Reporting Program))
  • IRB #12-021
  • 12-021
  • CDR0000737062
  • 9026 (Andere identificatie: Memorial Sloan Kettering Cancer Center)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren